denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Symposia: Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies
Program: Scientific Workshops
Friday, December 6, 2024: 4:18 PM-4:54 PM
Room 28 A-D
(San Diego Convention Center)
Moderator:
and
Ash A. Alizadeh, MD, PhD, Stanford University
Disclosures:
Alizadeh: BMS: Research Funding; Pharmacyclics: Consultancy; Forty Seven: Other: stock; Roche: Consultancy; Gilead: Consultancy; Foresight: Consultancy, Other: Scientific Co-founder; CiberMed: Consultancy, Other: Scientific Co-founder; CARGO Therapeutics: Divested equity in a private or publicly-traded company in the past 24 months; ADC Therapeutics: Consultancy; Adaptive Biosciences: Consultancy.
In contrast to lymphoma, B-cell acute lymphoblastic leukemia very commonly loses wild-type antigen expression in becoming resistant to CD19 CAR-T cells. Multiple mechanisms within the cell my drive this phenomenon, which has directly informed development of novel strategies, including co-targeting of additional receptors on malignant cells. This session will cover drivers of antigen loss and strategies to overcome this category of resistance in B-ALL.